



**Teratogenic potential of nano-incapsulated vitamin A
evaluated on an alternative model organism, the tunicate
Ciona intestinalis.**

Journal:	<i>International Journal of Food Sciences and Nutrition</i>
Manuscript ID	Draft
Manuscript Type:	Research Paper
Date Submitted by the Author:	n/a
Complete List of Authors:	Pennati, Roberta; Università degli Studi di Milano, Department of environmental science and policy; Manenti, Raoul; Università degli Studi di Milano, Department of environmental science and policy Stillitano, Antonella; Università degli Studi di Milano, Department of environmental science and policy Ficetola, Gentile; Università degli Studi di Milano, Department of environmental science and policy Scari, Giorgio; Università degli Studi di Milano, Department of environmental science and policy Mercurio, Silvia; Università degli Studi di Milano, Department of environmental science and policy Menegola, Elena; Università degli Studi di Milano
Keywords:	Functional food, Retinol, Bioavailability, ascidian

SCHOLARONE™
Manuscripts

1
2
3 **Teratogenic potential of nano-encapsulated vitamin A evaluated on an**
4 **alternative model organism, the tunicate *Ciona intestinalis*.**
5
6

7
8 Roberta Pennati¹, Raoul Manenti¹, Antonella Stillitano¹, **Gentile Francesco**
9 **Ficetola¹**, Giorgio Scari², Silvia Mercurio¹, Elena Menegola¹
10
11

12 ¹*Department of Environmental Science and Policy, University of Milano, Milano, Italy*

13 ²*Department of Biosciences, University of Milano, Milano, Italy*
14

15
16
17
18 Corresponding author: Roberta Pennati, Department of Environmental Science and
19 Policy, University of Milano, Via Celoria 2, 20133 Milano, Italy.
20

21
22 Phone: +39 02 50314765
23

24
25 e-mail: roberta.pennati@unimi.it
26

27
28 Roberta Pennati was born in 1969 and graduated in Natural Sciences in 1993 at the
29 University of Milano. She awarded a Ph.D. Degree in Natural and Environmental Sciences
30 in 1998 at the University of Milano. Since 2002, she is research associate in Zoology at
31 the Department of Biosciences, University of Milano. Her scientific activity concerns
32 mainly developmental neurobiology of marine invertebrates with particular regard to
33 tunicates.
34
35
36
37
38
39

40
41 Raoul Manenti: Department of Environmental Science and Policy, University of
42 Milano, Via Celoria 2, 20133 Milano, Italy. Phone: +393490733107
43

44
45 e-mail: raoulmanenti@gmail.com
46

47
48 Raoul Manenti graduated in Natural Sciences in at the University of Milano and Ph.D.
49 in Animal Biology, he performs researches in different fields of the zoology, from
50 developmental biology to herpetology. Currently he works as free-lance naturalist and
51 collaborates with the Department of Environmental Science and Policy of the
52 University of Milan.
53
54
55
56
57
58
59
60

1
2
3 Antonella Stillitano: Via Maurizio Quadrio, 20 – 20154 Milano, Italy.

4
5 Phone:+39331321058

6
7 e-mail: antonstill@gmail.com

8
9
10 Antonella Stillitano graduated in Biology Applied to Sciences of Nutrition at the
11 University of Milan, Department of Biosciences, Italy. She was internship at the Unit
12 Clinic of Metabolic Diseases and Diabetes of A.O. S. Paolo, Milan, Italy. Currently she
13 works as professional nutritionist.
14
15

16
17
18 Gentile Francesco Ficetola: Department of Environmental Science and Policy,
19 University of Milano, Via Celoria 2, 20133 Milano, Italy.
20

21
22 **Gentile Francesco Ficetola After a degree in natural sciences, Gentile Francesco**
23 **Ficetola awarded a PhD in Environmental Sciences. He is a researcher combining**
24 **genetic and statistical tools to understand the impact human activities and of**
25 **environmental modifications on multiple levels of biodiversity.**
26
27

28
29
30 e-mail: Francesco.ficetola@unimi.it

31
32
33 Giorgio Ulisse Scari: Department of Biosciences, University of Milano, via Celoria 26,
34 20133 Milano, Italy. Phone: +39 02 50314754

35
36
37 e-mail: giorgio.scari@unimi.it

38
39
40 Giorgio Ulisse Scari: in1992 awarded the Ph.D. in ecology and evolutionary biology at
41 the University of Milano. He is research associate at the Department of Biosciences,
42 University of Milano. His research activity is mainly performed in the frame of Cell
43 Biology, and its focused to the settling of synthesis methodologies, treatments and
44 structural/functional characterizations of cells using nanocomposites and nanoparticles.
45
46
47

48
49
50 Silvia Mercurio: Department of Environmental Science and Policy, University of
51 Milano, Via Celoria 2, 20133 Milano, Italy. +39 0250314755

52
53
54
55
56 e-mail: sil.mercurio@gmail.com

1
2
3 Silvia Mercurio graduated in Biodiversity and Evolutionary Biology in 2010 at the
4 University of Milano. She award a Ph.D. Degree in Animal Biology. Since 2014, she is
5 postdoc fellow at the Department of Biosciences, University of Milano. Her scientific
6 activity concerns developmental biology of invertebrate deuterostomes.
7
8
9

10
11
12
13 Elena Menegola: Department of Environmental Science and Policy, University of
14 Milano, Via Celoria 2, 20133 Milano, Italy.
15
16

17
18 Elena Menegola graduated in Biological Science in 1990. She is Associate Professor of
19 Comparative Anatomy at the University of Milano. Her main scientific interest
20 concerns embryo development in alternative model animals to analyse the pathogenic
21 pathways of congenital malformation following exposure to xenobiotics.
22
23
24

25 elena.menegola@unimi.it
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Teratogenic potential of nano-encapsulated vitamin A evaluated on an alternative model organism, the tunicate *Ciona intestinalis*.

Nano-encapsulation is a technology used to pack substances in order to enhance stability and bioavailability that may interact with living systems causing unexpected toxicity. Vitamin A is one of the substances that has received attention, as in developed countries the increasing availability of supplements is leading to its excessive intake. This study aims to compare teratogenic effects caused by exposition to the traditional formulation of Vitamin A and nano-encapsulated Vitamin A. We used ascidian embryos as alternative models. Ascidians are marine organisms strictly related to vertebrates that share with them the same body plan and developmental program, including the morphogenetic role of retinoic acid (RA). Our data showed that adverse effects of exposure to the same concentration of the two formulations were different suggesting that the nano-encapsulation increased the bioavailability of the molecule that could be better absorbed and metabolized to RA, the effective teratogenic substance.

Keywords: functional food, retinol, ascidian, bioavailability.

Introduction

Nano-encapsulation is a novel technology used to pack substances in miniature. It is generally used to deliver different nutraceutical products and bioactive molecules such as vitamins and antioxidants, allowing production of functional foods with enhanced functionality and stability.

Lipid-based nano-encapsulation systems enhance the performance of lipophilic molecules by improving their solubility. In these systems, a lipophilic core is surrounded by an amphiphilic shell made of surface-active material that enhances solubility in aqueous media. Thus, nano-encapsulation can provide significant savings to formulators, as it allows to reduce the amount of active ingredients, increasing their bioavailability (Astete et al., 2009).

Moreover, several studies showed that the bioavailability of highly lipophilic substances encapsulated within lipid droplets increases as the droplet size decreases (Acosta, 2009). It has been proposed that the larger surface area of small droplets could allow quicker digestion leading to easier content release and absorption. In addition, small droplets

1
2
3 have longer residence time in the small intestine and they can be directly transported
4 across the epithelium by paracellular or transcellular mechanisms (McClements et al.,
5 2011).
6

7
8 Besides, it is well known that nanoparticles furnish new chemical and physical
9 properties, different from normal bulk formulation, and they may interact with living
10 systems causing unexpected toxicity (Das et al., 2009). Indeed, there has been growing
11 concern about the increased utilization of nanoparticles in foods and beverages because
12 of potential toxic effects (Hagens et al., 2007; Chaudhry et al., 2008; Bouwmeester et
13 al., 2009; Souto et al., 2009). Reducing the dimensions of a material to nanometer
14 region may modify its biological fate within human body, such as absorption,
15 distribution, metabolism, and excretion processes, thereby altering its potential for
16 promoting toxicity (Hagens et al., 2007; Bouwmeester et al., 2009).
17
18

19
20 Since nanomaterials are essentially different from their corresponding bulk
21 formulations, the European Food Safety Agency (EFSA) and the Food and Drug
22 Administration (FDA) recommended to carefully evaluate and monitor nano-formulated
23 molecules since they can potentially cause risks to human health and environment
24 (EFSA 2011).
25
26

27
28 On this regard, vitamin A is one of the vitamins which has received much attention as in
29 developed countries the increasing availability of supplements is leading to excessive
30 vitamin A intake (Penniston and Tanumihardjo, 2006), an even growing problem when
31 considering nano-formulation diffusion.
32
33

34
35 Vitamin A (retinol) is mainly obtained from animal food. Once retinol has been taken
36 up by a cell, it can be oxidized to retinal (retinaldehyde) by retinol dehydrogenases and
37 then retinaldehyde can be oxidized to retinoic acid (RA) by aldehyde dehydrogenases
38 (ALDHs).
39
40

41
42 RA is a morphogen known to play key roles during embryonic development of both
43 vertebrate and invertebrate chordates (Canestro, 2006). RA levels are finely tuned in
44 embryos by a precise balance between ALDH synthetic activity and the catalytic
45 activity of CYP26, a cytochrome P450 enzyme. Embryos deprived of RA showed
46 defects in different organs including eyes, heart, lungs and genital tract whereas early
47 exposure to exogenous RA caused mainly defects in the anterior-posterior (AP)
48 patterning of their neural tubes (Shimeld, 1998). Indeed, it has been demonstrated that
49 in chordates RA regulates the patterning of the antero-posterior embryo body axis by
50 controlling the expression of several HOX genes (Shimeld, 1998).
51
52
53
54
55
56
57
58
59
60

1
2
3 Ascidians are chordates belonging to the Tunicate taxon that is considered the sister
4 group of vertebrates (Delsuc et al., 2006). Adult ascidians are filter feeding sessile
5 marine organisms; they develop through a swimming larva that retains the ancestral
6 chordate body plan formed by a trunk and a locomotory tail where the notochord is
7 located. A dorsal hollow neural tube constitutes the central nervous system; on the base
8 of gene expression pattern, it can be subdivided in different regions homologue to
9 forebrain, hindbrain and posterior neural tube of vertebrates (Passamanek and Di
10 Gregorio, 2005). Thus, ascidians, conjugating the handiness of an invertebrate with the
11 body plan of a vertebrate, could represent an alternative model to investigate the
12 toxicological potential of nano-molecules.

13
14 Exposure of ascidian gastrulae to exogenous RA causes a typical and highly
15 reproducible phenotype characterized by round trunk (Nagatomo et al., 2003; De
16 Bernardi et al., 1994). In the ascidian *Ciona intestinalis*, it has been demonstrated that
17 exogenous RA upregulates *Ci-Cyp26* expression and slightly downregulates *Ci-Aldh2*
18 expression in the embryo (Nagatomo and Fujiwara, 2003). Moreover, RA strongly
19 enhances *Hox-1* expression both in *C. intestinalis* and in *Halocynthia roretzi* (Nagatomo
20 and Fujiwara, 2003, Katsuyama et al., 1995).

21
22 In this work, we exposed ascidian embryos to nano-encapsulated and bulk vitamin A in
23 order to compare the effects induced by the two formulations. We assumed that
24 differences in the effects observed after treatment to the same concentrations could be
25 attributed to the augmented bioavailability of the nano formulation thus obtaining an
26 indirect assessment of its toxicity.

27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 **Material and Method**

43 44 *Animals*

45
46 Adults of *Ciona intestinalis* were obtained by the fishery service of the Station
47 Zoologique de Roscoff (France) and were maintained in aquaria filled with artificial
48 seawater (Instant Ocean; salinity about 32‰) and provided with internal circulation
49 system as well as mechanical, chemical and biological filters. Constant illumination was
50 preferred to prevent spontaneous release of gametes. Sperm and eggs were obtained
51 surgically from animal gonoducts and used for *in vitro* fertilization in artificial sea water
52 (ASWH: 122.75g NaCl, 3.35g KCl; 7.35g CaCl₂ 2H₂O; 22.40g MgCl₂ 6H₂O; 31.45g
53
54
55
56
57
58
59
60

1
2
3 MgSO₄ 7H₂O; 0.90g NaHCO₃; 25ml 1M HEPES in 1l of H₂O), in order to obtain
4 synchronously dividing embryos.
5
6

7 8 **Treatments**

9 Embryos at gastrula stage (4.9 hours post fertilization (hpf); Hotta et al., 2007) were
10 exposed to different concentrations of retinol palmitate, the esterified and biological
11 active form of vitamin A (Sigma, Italy), from here on bulk vitamin A (vit A), and to
12 nanoencapsulated retinol palmitate (Aquanova® Novasol® GmbH, Germany), from
13 here on nano vit A.
14

15 Tested concentrations for both formulations were: 2 IU/ml, 10 IU/ml e 20 IU/ml.
16 Concentrations were chosen on the basis of previously reported effective concentrations
17 of retinol on ascidian embryos (Groppelli et al., 2001).
18

19 Nano vit A is supplied as a 10% emulsion of nanoliposomes, formed by a shell of lipids
20 from soya lecithin and a core of retinol palmitate. Stock solution of nano vit A was
21 prepared diluting 11 µl of emulsion in 20 ml of ASWH and heating at 37°C for 15 min
22 with gentle rocking. Working solutions were prepared diluting respectively 0.8, 4 and 8
23 ml of stock solution to a final volume of 40ml in ASWH.
24

25 1 M stock solution of bulk vit A corresponds to a 10.876 IU/ml concentration. Working
26 solutions were prepared diluting respectively 736, 368 and 73.6 µl of stock solution to a
27 final volume of 40 ml of ASWH.
28

29 *C. intestinalis* embryos at gastrula stage were treated in glass Petri dishes (4 cm
30 diameter) containing 40 ml of working solution or 40 ml of ASWH as control. An
31 independent experiment was performed to test the effects of the nanoliposomes
32 exposing embryos to the empty shells of soya lecithin (Aquanova® Novasol® GmbH,
33 Germany). Each treatment was repeated 3 times on different batches. At least 50
34 embryos were exposed for each treatment. All treatments were performed at 18 °C in a
35 thermostatic room. Embryos were allowed to develop until they reached the hatching
36 larva stage (17.5 hpf; Hotta et al., 2007) and then fixed in 4% paraformaldehyde for 1 h
37 for following analysis.
38
39
40
41
42
43
44
45
46
47
48
49
50

51 52 **Morphological and statistical analysis**

53 Control and treated larvae were mounted on glasses for microscopic observations. Dead
54 embryos and severely affected ones were counted. For the residual samples, the
55 incidence of malformations at adhesive papillae, pigmented organs, trunk and tail was
56
57
58
59
60

1
2
3 scored. We used generalized linear models to assess the impact of treatment and dose on
4 larval mortality, and on the frequency of malformed individuals.

5
6 Subsequently, we repeated the analysis of the frequency of malformations on different
7 portions of the body: adhesive papillae, pigmented organs, tail and trunk.

8
9 In all models, we used a quasi-binomial error distribution to take into account
10 overdispersion, and we calculated significance using a F test (Maindonald and Braun,
11 2010). All analyses were performed using the R statistical environment (Maindonald
12 and Braun, 2010).

13
14 A chi-square test was performed to disentangle differences between controls and
15 embryos exposed to empty nanoliposomes. A p value ≤ 0.05 was considered significant.
16
17
18
19

20 21 *Immunostaining*

22 Larvae exposed to 10 and 20 IU/l of bulk and nano vit A were processed for
23 immunostaining of nervous fibers with a monoclonal anti β tubulin antibody (Sigma,
24 clone 2-28-33).
25
26

27 Control and treated larvae were fixed in 4% PFA in 0.1M phosphate buffer saline (PBS)
28 at room temperature for 2 h. All the following steps were performed with gentle
29 rocking. Specimens were permeabilized with 0.1% Tween-20, 0.25% Triton X-100 in
30 PBS for 1 h, were washed three times in PBS for 10 min each, and incubated for 2 h in
31 50% PBS/50% normal goat serum. Then, the samples were incubated overnight at 4°C
32 with primary antibody diluted 1:400. After several washes in PBS, the samples were
33 incubated in 1% bovine serum albumin (BSA) in PBS for 2 h at room temperature, and
34 then incubated at 4°C overnight in goat anti-mouse AlexaFluor 488 diluted 1:800 in
35 PBS. After several washes in PBS, samples were mounted in 1,4-
36 diazabicyclo[2,2,2]octane (DABCO, Sigma, Italy) on microscope slides and examined
37 using a confocal laser scanning microscope Leica TCSNT (Leica Microsystems,
38 Heidelberg, Germany), equipped with laser argon/krypton, 75mW multiline. Series of
39 “optical sections” attained by scanning whole-mount specimens were projected into one
40 image with greater focal depth.
41
42
43
44
45
46
47
48
49
50

51 52 *In situ hybridization*

53 Control and treated larvae were fixed in fresh 4% paraformaldehyde in 0.5M NaCl and
54 0.1M MOPS at pH 7.5, at room temperature for 90 min. Then, samples were washed
55 twice with PBT (0.1% Tween-10% in PBS) and digested with 2 μ g/ml Proteinase K for
56
57
58
59
60

1
2
3 30 min at 37°C. Next, samples were post-fixed in 4% paraformaldehyde in PBS for 1 h,
4 washed twice in PBT and then three times, 10 min each, with 0.25% acetic anhydride in
5 0.1M triethanolamine. Samples were then incubated in the hybridization solution (50%
6 formamide, 5×SSC, 50µg/ml tRNA, 5× Denhardt's solution, 0.1% Tween-10%,
7 50µg/ml heparin) for 1 h. The hybridization was carried out overnight at 50°C with 0.3–
8 0.6 ng/µl Dig-labelled probe. *Ci-Otx* and *Ci-Hox-1* dig labelled antisense RNA was
9 obtained by linearized plasmids using the dig-labelling kit (Roche, Italy) according to
10 the indications. On the second day, samples were washed with a descending series of
11 SSC buffer in 50% formamide and 0.1% Tween-10% then incubate overnight at 4°C in
12 a dilution (1:2000) of alkaline phosphatase-conjugated anti-DIG-antibody in blocking
13 buffer containing 0.5% blocking reagent and 5% normal sheep serum. On the third day,
14 samples were washed several times in PBT and then rinsed with AP buffer containing
15 NBT/BCIP substrates. When color reaction developed, larvae were washed in PBT,
16 mounted on glass slides with 80% glycerol and observed using an optical microscope.
17
18
19
20
21
22
23
24
25
26

27 28 **Results**

29 30 31 *Morphological analysis*

32 Control larvae of *Ciona intestinalis* showed a normal phenotype characterized by an
33 elongated trunk, pigmented organs correctly located in the sensory vesicle, three
34 anterior palps well differentiated (Fig. 1A,B). Larvae exposed to low concentrations (2
35 IU/ml) of nano and bulk vit A showed a conserved morphology even if in some rare
36 cases their palps were not elongated (Fig. 1C,F). Larvae exposed to the higher
37 concentrations of vitamin A (10 IU/ml) nano and bulk showed recurrent malformations:
38 palps were not correctly developed or were absent; pigmented organs were fused and
39 dislocated in the upper side of the sensory vesicle; the trunk was roundish (Fig. 1D,G).
40 Larvae exposed to the highest tested concentrations (20 IU/ml) of bulk vit A showed the
41 same altered phenotypes (Fig. 1E). Instead, exposure to 20 IU/ml nano vit A caused a
42 prevalent more severe phenotype characterized by a short trunk, short and curled tail,
43 and absence of palps (Fig. 1H). Larvae exposed to the empty shell of soya lecithin were
44 similar to control reared in ASWH (data not showed).
45
46
47
48
49
50
51
52
53
54

55 56 *Incidence of malformations*

57
58
59
60

1
2
3 Larvae developed from embryos exposed to Nano and Bulk Vitamin A were scored to
4 obtain the proportion of not developed, healthy and malformed specimens. Resulting
5 data were statistically analyzed to evaluate the effects of treatment, dose and the
6 interaction of dose and treatment. Percentage of not developed larvae is not influenced
7 by the treatment ($F_{1,14} = 0.52$; $P = 0.48$), by the dose ($F_{2,14} = 1.01$; $P = 0.38$) or by the
8 interaction between dose and treatment ($F_{2,14} = 1.26$; $P = 0.31$). These results prove
9 that the two tested formulations of Vitamin A have no toxic effects on ascidian embryos
10 and larvae.

11
12 Instead, statistical analysis showed a significant effect of dose ($F_{2,14} = 15.05$; $P =$
13 0.002) and of treatment ($F_{1,14} = 10.77$; $P = 0.005$) on the incidence of malformed
14 specimens, but not of the interaction between dose and treatment ($F_{2,14} = 1.26$, $P =$
15 0.31). The dose dependent incidence of malformations with both the formulations
16 confirms that the teratogenic properties of Vitamin A are maintained following nano
17 encapsulation. The most striking result is the significant effect of the two different
18 formulations on the incidence of malformations, indicating that at the same dose the
19 number of malformed specimens is higher after exposure to the nano encapsulated
20 Vitamin A than to bulk Vitamin A. Figure 2A shows that exposure to 20 IU/ml Nano
21 Vitamin A causes more than 50% of malformed larvae (53.4%), whereas the proportion
22 of malformed larvae caused by the same dose of bulk Vitamin A is 11%.

23
24 Larvae exposed to the empty shell of soya lecithin showed an incidence of malformed
25 larvae very low and not significantly different from that of controls reared in ASWH
26 (chi-square test: $P = 0.3105$). To better characterize the malformations induced, we
27 identified four target organs and scored the exposed larvae according the presence of
28 anomalies in these structures. From anterior to posterior these targets are: adhesive
29 papillae, pigmented organs, trunk and tail. Data are reported in Table 1 and graphs in
30 figure 2B-E.

31
32 For the incidence of malformation to the adhesive papillae, there is a significant effect
33 of the dose, but not of the treatment, that means that both the formulations of vit A have
34 a similar dose dependent effect on the papillae, the anterior most organs. The incidence
35 of malformations to the pigmented organs is significantly dependent by the dose and by
36 the interaction between dose and treatment; in other words the differences between the
37 two formulations are evident only at the highest tested doses. For the trunk
38 malformations there are significant effects of concentrations and treatments. The
39 interaction between concentration and treatment suggests that the differences between
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 the two formulations are wider at the highest concentrations. Finally, there are no
4 significant differences in the incidence of malformations of the tail, the more posterior
5 organ of the larva.
6
7
8

9 10 ***Immunostaining***

11 To better characterize induced malformations, we performed an immunostaining of the
12 nervous system fibers of the larvae treated with the highest concentrations of nano and
13 bulk vitamin A using an anti β -tubulin monoclonal antibody. In control larvae, the
14 fibers of central and peripheral nervous system resulted well marked; in particular,
15 papillary neurons and papillary nerves that run from the adhesive papillae to the
16 posterior sensory vesicle were clearly recognizable (Fig. 3A). In the sensory vesicle,
17 several fibers occurred in correspondence of the pigmented sensory organs, the otolith
18 and the ocellus, as clearly visible in the image obtained by the superimpositions of
19 confocal and transmission microscopy images (Fig. 3B). From the posterior part of the
20 sensory vesicle, the neural tube fibers run posteriorly into the dorsal tail (Fig. 3A). The
21 larvae exposed to 20 IU/ml bulk vit A showed the papillary nerves and neural fibers
22 around the pigmented organs displaced more dorsally (Fig. 3C) as compared to control
23 larvae (Fig. 3A); moreover the point of insertion of the sensory papillary nerves into the
24 sensory vesicle was not clearly detectable. Fibers of the posterior neural tube were
25 normally developed (Fig. 3C,D). Nervous fibers of the trunk of larvae exposed to 20
26 IU/ml nano vit A were compromised severely. In particular, papillary nerves showed an
27 abnormal pathway and were shorter than those of control larvae. Moreover, the fibers
28 around pigmented organs were not detectable and the sensory vesicle was shifted
29 anteriorly (Fig. 3E,F).
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44

45 ***In situ hybridization***

46 Defects to the sensory vesicle in exposed larvae were evidenced also by *in situ*
47 hybridization experiments with a probe for *Ci-Otx*. In *Ciona intestinalis* larvae, *Ci-Otx*
48 is expressed exclusively in the sensory vesicle (Wada and Satoh, 2001) (Fig. 4A,B). In
49 20 IU/ml bulk vitamin A larvae, the region of expression of *Ci-Otx* was reduced
50 indicating a reduction of the overall dimension of the sensory vesicle (Fig. 4C,D). In
51 larvae exposed to 20 IU/ml nano vit A the sensory vesicle was slightly reduced as
52 compared to larvae exposed to the bulk formulation and resulted displaced dorsally
53 (Fig. 4E,F).
54
55
56
57
58
59
60

1
2
3 To verify that the observed malformations were due to a specific effect of Vitamin A,
4 we analyzed the expression of *Ci-Hox-1* in control and exposed larvae. *Ci-Hox-1*
5 expression in greatly enhanced in *Ciona intestinalis* larvae by exposure to Retinoic Acid
6 (RA), the active metabolite of Vitamin A (Nagatomo and Fujiwara, 2003). In control
7 larvae, *Ci-Hox-1* was expressed in the endoderm of the trunk and in the neural tube, at
8 level of visceral ganglion and in the first tract of the posterior nerve cord (Fig. 4G). In
9 larvae exposed to 20 IU/ml bulk vit A, the limit of expression of *Ci-Hox-1* in the neural
10 tube was shifted posteriorly (Fig. 4H). This shift was more marked in larvae exposed to
11 the nano formulation of Vitamin A (Fig. 4I). These results suggested that the observed
12 effects were attributable to the action of Vitamin A that upon its absorption is
13 metabolized to RA.
14
15
16
17
18
19
20
21

22 Discussion

23
24
25
26 In this paper, we analyzed the effects that Vitamin A exposure on the development of *C.*
27 *intestinalis* embryos. Moreover, we compared the effects induced by two different
28 formulations of this molecule, bulk and nano-encapsulated, to evaluate if the latter can
29 increase vitamin bio-availability.
30
31

32 Morphological analysis of exposed larvae indicated that vitamin A caused
33 malformations similar to those observed after Retinoic Acid (RA) treatment principally
34 affecting adhesive papillae, trunk and pigmented organs (Nagatomo et al., 2003;
35 Katsuyama et al., 1995). Retinoic acid is the active metabolite of Vitamin A and is
36 known to be a morphogen implicated in a wide range of biological processes during
37 differentiation and morphogenesis including patterning of antero-posterior body axis
38 (Maden and Holder, 1992). Generally, ascidian embryos exposure to RA results in a
39 typical larval phenotype characterized by round trunk, reduced adhesive papillae, fusion
40 of pigmented organs and extrusion of the sensory vesicle (Nagatomo et al., 2003).
41
42
43
44
45
46
47

48 In our experiments, we obtained the same phenotype, that was particularly accentuated
49 in the samples exposed to the nano formulation.
50

51 Moreover, the incidence of malformations caused by exposure to vitamin A was dose
52 and formulation dependent. Low concentrations of both formulations did not cause a
53 significant increase of malformations as compared to controls. 2 IU/ml is the no
54 observed effect level (NOEL) for both bulk and nano formulations of Vitamin A for *C.*
55 *intestinalis* embryos. Whereas higher concentrations of nano-incapsulated Vitamin A
56
57
58
59
60

1
2
3 induced a significant increment of severely malformed larvae as compared to the same
4 concentration of the bulk form. We excluded the possibility that nanoliposomes are
5 responsible of the observed malformations since treatments with empty shells did not
6 caused any significant effect.
7
8

9
10 In addition, the severity of the induced malformations was dependent by the
11 formulation. Immunolabelling of nervous fibers revealed that the anterior papillary
12 nerves and the nervous fibers around the pigmented organs were more severely affected
13 after exposure to the highest concentration of nano vit A than to the same concentration
14 of the bulk form. The sensory vesicle, as shown by in situ hybridization with a *Ci-Otx*
15 probe, was reduced and displaced dorsally following the exposure to nano vit A. This is
16 a typical alteration caused by RA. The effects of exposure to the same concentration of
17 the bulk form were less evident.
18
19

20
21 Considering all these aspects, our results suggested that the nano-encapsulation
22 increased the bioavailability of the molecule that could be better absorbed and
23 metabolized to RA. This observation is strengthened by the analysis of expression of
24 *Ci-Hox-1* in control and exposed larvae. In *Ciona intestinalis* larvae, *Ci-Hox-1* is
25 expressed with a sharp posterior limit in the nerve cord (Ikuta et al., 2005) and is
26 inducible by exogenous RA (Nagatomo and Fujiwara, 2003). The increased expression
27 of this gene in Vitamin A exposed larvae indicated that in these larvae the levels of RA
28 augmented following an increment of the supply of its precursor. These data suggested
29 that high concentrations of Vitamin A are teratogenic for ascidian larvae probably by
30 inducing an increment of endogenous RA synthesis. Even though this seems to be the
31 more plausible action of Vitamin A, it cannot be excluded that other mechanisms could
32 be present, and the exact pathway of teratogenicity of this molecule need to be
33 confirmed by further studies.
34
35

36
37 In any case, our data confirm that nano-incapsulated vit A differs in its effects to bulk
38 formulation at the same doses and can potentially be a risk to human health.
39
40

41
42 In the last decade, much attention has been paid to project delivery systems to increase
43 the bioavailability of approved food grade nutrients and bioactive substances, in order to
44 produce functional foods or fortified foods, requested by consumers. Food products are
45 normally fortified with health promoting and disease preventing molecules such as
46 phytochemicals, vitamins, minerals, oils (omega 3 fatty acids) (Adytia et al., 2017).
47
48

49
50 In developed nations, due to fortified food, observational studies suggest that more than
51 75% of people may be routinely ingesting more than the recommended dietary
52
53
54
55
56
57
58
59
60

1
2
3 allowance (RDA) for vitamin A (Allen and Haskell, 2002). The use of
4 nanoencapsulated vit A can increase the risk of hyper-vitaminosis in these situations.
5 Thus, our results suggest that it is necessary to carefully monitor beverage and food
6 supplementation with nano-vit A and reconsider the RDA in the light of its augmented
7 bioavailability, in accordance with recommendations of European Food Safety Agency
8 (EFSA) and the Food and Drug Administration (FDA).
9
10
11
12

13
14 **Acknowledgments:** The authors want to thank the people of “IBIS: imaging bioscience
15 support” for the use of confocal microscope.
16
17

18
19 **Disclosure of interest:** the authors report no conflicts of interest.
20
21

22 23 24 **References**

25
26
27 Acosta E. 2009. Bioavailability of nanoparticles in nutrient and nutraceutical delivery. *J.*
28 *Colloid Interface Sci* 14: 3-15.
29

30
31
32 Aditya NP, Espinosa YG, Norton IT. 2017. Encapsulation systems for the delivery of
33 hydrophilic nutraceuticals: food application. *Biotechnology Advances*
34

35
36
37 Allen LH, Haskell M. 2002. Estimating the potential for vitamin A toxicity in women
38 and young children. *J Nutr.* 132:2907S–19S.
39

40
41
42 Astete CE, Sabliov CM, Watanabe F, Biris A. 2009. Ca²⁺ cross-linked alginic acid
43 nanoparticles for solubilization of lipophilic natural colorants. *J Agric Food Chem.*
44 *57:7505–7512.*
45
46
47

48
49 Bouwmeester H, Dekkers S, Noordam MY, Hagens WI, Bulder AS, de Heer C, ten
50 Voorde SECG, Wijnhoven SWP, Marvin HJP, SipsAJAM. 2009. Review of health
51 safety aspects of nanotechnologies in food production. Review of health safety aspects
52 of nanotechnologies in food production, *Regulatory Toxicology and Pharmacology.*
53 *53:52-62.*
54
55
56
57
58
59
60

- 1
2
3 Canestro C, Postlethwait JH, Gonzalez-Duarte R, Albalat R. 2006. Is retinoic acid
4 genetic machinery a chordate innovation? *Evol. Dev.* 8:394–406
5
6
7
8 Chaudhry Q, Scotter M, Blackburn J, Ross B, Boxall A, Castle L, Aitken R, Watkins R.
9 2008. Applications and implications of nanotechnologies for the food sector, *Food*
10 *Additives & Contaminants: Part A*, 25:3, 241-258, DOI:10.1080/02652030701744538
11
12
13
14 Das M, Saxena N, Dwivedi PD. 2009. Emerging trends of nanoparticles application in
15 food technology: Safety paradigms. *Nanotoxicology*. 3:10–18.
16
17
18
19 De Bernardi F, Sotgia C, Ortolani G. 1994. Retinoic acid treatment of ascidian embryos:
20 Effects on larvae and metamorphosis. *Anim Biol* 3: 75–81.
21
22
23
24 Delsuc F, Brinkmann H, Chourrout D, Philippe H., 2006. Tunicates and not
25 cephalochordates are the closest living relatives of vertebrates. *Nature*. 439, 965–968.
26
27
28
29 EFSA Scientific Committee. 2011. Guidance on the risk assessment of the application
30 of nanoscience and nanotechnology in the food and feed chain. *EFSA Journal* 9: 2140.
31
32
33
34 Gropelli S, Pennati R, Sotgia C, De Bernardi F. 2001. AChE localization in the
35 adhesive papillae of the ascidian larvae: effects of citral, a retinoic acid synthesis
36 inhibitor. *Invertebr Reprod Dev*. 40: 95-102.
37
38
39
40 Hagens WI, Oomen AG, de Jong WH, Cassee FR, Sips AJ. 2007. What do we (need to)
41 know about the kinetic properties of nanoparticles in the body? *Regul Toxicol*
42 *Pharmacol*. 49:217-229.
43
44
45
46
47 Hotta K, Mitsuhashi K, Takahashi H, Inaba K, Oka K, Gojoboti T, Ikeo K. 2007. A
48 web-based interactive developmental table for the ascidian *Ciona intestinalis*,
49 including 3D real-image embryo reconstructions: I. From fertilized egg to
50 hatching larva. *Dev Dyn* 236:1790-805.
51
52
53
54
55
56 Ikuta T and Saiga H. 2005. Organization of Hox genes in ascidians: present, past and
57 future. *Dev Dyn* 233:382-389.
58
59
60

1
2
3
4 Katsuyama Y, Wada S, Yasugi S, Saiga H, 1995. Expression of the labial group Hox
5 gene *HrHox-1* and its alteration induced by retinoic acid in development of the ascidian
6 *Halocynthia roretzi*. *Development* 121: 3197–3205.
7
8

9
10
11 Maden M, Holder N. 1992. Retinoic acid and development of the central nervous
12 system. *Bioessays* 14:431-438.
13

14
15
16 Maindonald, J., Braun, W.J., 2010. Data analysis and graphics using R. Cambridge
17 University Press, Cambridge.
18

19
20
21 McClements DJ, Rao J. 2011. Food-grade nanoemulsion: formulation, fabrication,
22 properties, performance, biological fate and potential toxicity. *Crit Rev Food Sci.* 51:
23 285-330.
24
25

26
27
28 Nagatomo K, Ishibashi T, Satou Y, Satoh N, Fujiwara S. 2003. Retinoic acid effects
29 gene expression and morphogenesis without upregulating the retinoid acid receptor in
30 the ascidian *Ciona intestinalis*. *Mech Dev.* 120: 363-372.
31
32

33
34
35 Nagatomo K, Fujiwara S. 2003. Expression of *Raldh2*, *Cyp26* and *Hox-1* in normal and
36 retinoic acid-treated *Ciona intestinalis* embryos. *Gene Expr Patterns.* 3:273–277.
37
38

39
40
41 Passamaneck YJ, Di Gregorio A. 2005. *Ciona intestinalis*: chordate development made
42 simple. *Dev Dyn.* 233:1-19.
43

44
45
46 Penniston KL, Tanumihardjo SA. 2006. The acute and chronic toxic effects of vitamin
47 A. *Am J Clin Nutr* 83:191-201.
48

49
50
51 Souto EB, Martins-Lopes P, Lopes CM, Gaivão I, Silva AM, Guedes-Pinto H. 2009. A
52 note on regulatory concerns and toxicity assessment in lipid-based delivery systems
53 (LDS). *J Biomed Nanotechnol.* 5:317-322.
54

55
56
57 Wada H, Satoh N. 2001. Patterning the protochordate neural tube. *Curr Opin Neurobiol*
58 11:16-21.
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1: Typical phenotypes obtained after exposure to bulk and nano vit A. A Control larva. B. Schematic drawing of the anatomy of a larva, main organs are indicated with a color code. C-E: larvae exposed to bulk vit A. F-H: larvae exposed to Nano- vitamin A. Scale bar: 100µm.

Figure 2: Graphs indicating the incidence of severely malformed larvae (A) and the incidence of the malformations at target organs (B-D) after exposure to different concentrations of bulk and nano vit A. The values are in percentage and standard deviation is indicated.

Figure 3: Confocal laser microscope images of the trunk of the larvae. Nervous fibers are immunolabelled with anti-β tubulin antibody. A,B: Control larva. C,D: larva exposed to 20 IU/ml bulk vit A. E,F: larva exposed to 20 IU/ml nano vit A. B,D,E: superimposition of confocal microscope image with a transmission microscope one. ap, adhesive papilla; nt, neural tube; oc, ocellus; ot, otolith; pn, papillary neurons; sv, sensory vesicle.

Figure 4: In situ hybridizations. A-F: *Ci-Otx* expression. A,B: control larva. C,D: larva exposed to 20IU/ml bulk vitamin A. E,F: larva exposed to 20IU/ml nano vitamin A. G-I: expression of *Ci-Hox-1*. The arrow indicates the posterior limit of expression. G: control larva. H: larva exposed to 20 IU/ml bulk vitamin A. I: larva exposed to 20 IU/ml nano vitamin A. Scale bar. 100µm.

Table 1: Effect of dose and treatment on the frequency of malformations in the different body portions. Significant effects are in bold.





Figure 1: Typical phenotypes obtained after exposure to bulk and nano vit A. A Control larva. B. Schematic drawing of the anatomy of a larva, main organs are indicated with a color code. C-E: larvae exposed to bulk vit A. F-H: larvae exposed to Nano- vitamin A. Scale bar: 100µm.

164x57mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60






Figure 3: Confocal laser microscope images of the trunk of the larvae. Nervous fibers are immunolabelled with anti- β tubulin antibody. A,B: Control larva. C,D: larva exposed to 20 IU/ml bulk vit A. E,F: larva exposed to 20 IU/ml nano vit A. B,D,E: superimposition of confocal microscope image with a transmission microscope one. ap, adhesive papilla; nt, neural tube; oc, ocellus; ot, otolith; pn, papillary neurons; sv, sensory vesicle.

200x156mm (300 x 300 DPI)

Only




Figure 4: In situ hybridizations. A-F: Ci-Otx expression. A,B: control larva. C,D: larva exposed to 20IU/ml bulk vitamin A. E,F: larva exposed to 20IU/ml nano vitamin A. G-I: expression of Ci-Hox-1. The arrow indicates the posterior limit of expression. G: control larva. H: larva exposed to 20 IU/ml bulk vitamin A. I: larva exposed to 20 IU/ml nano vitamin A. Scale bar. 100 μ m.

106x93mm (300 x 300 DPI)

	concentration			treatment			concentration × treatment		
	<i>F</i>	d.f.	<i>P</i>	<i>F</i>	d.f.	<i>P</i>	<i>F</i>	d.f.	<i>P</i>
Adhesive papillae	11.08	2,14	0.001	0.18	1,14	0.67	1.61	2,14	0.24
Pigmented organs	8.43	2,14	0.004	1.82	1,14	0.20	5.24	2,14	0.02
Trunk	9.12	2,14	0.003	12.15	1,14	0.004	4.96	2,14	0.02
Tail	1.14	2,14	0.35	1.66	1,14	0.22	0.21	2,14	0.81

A

	controls	2 IU/ml bulk	10 IU/ml bulk	20 IU/ml bulk	2 IU/ml Nano	10 IU/ml Nano	20 IU/ml Nano
examined larvae	201	158	174	150	157	167	155
not developed	6 (2.99%)	19 (12.03%)	9 (5.17%)	15 (10.00%)	14 (8.92%)	17 (10.18%)	20 (12.90%)
severely malf. larvae	5 (2.49%)	0	8 (4.60%)	17 (11.33%)	5 (3.18%)	8 (4.79%)	81 (52.26%)
healthy larvae	190 (94.53%)	139 (87.97%)	157 (90.23%)	118 (78.67%)	138 (87.90%)	142 (85.03%)	54 (34.84%)

B

	controls	2IU/ml bulk	10 IU/ml bulk	20 IU/ml bulk	2 IU/ml Nano	10 IU/ml Nano	20 IU/ml Nano
examined larvae	116	115	140	125	99	74	87
malformed palps	14 (12.07%)	25 (21.74%)	81 (57.86%)	81 (64.80%)	16 (16.16%)	51 (68.925)	79 (90.80%)
malformed pig. organs	13 (11.21%)	9 (7.83%)	51 (36.43%)	23 (18.40%)	6 (6.06%)	23 (31.08%)	55 (63.22%)
malformed trunk	11 (9.485)	8 (6.96%)	14 (10.00%)	11 (8.80%)	4 (4.04%)	13 (17.57%)	59 (67.82%)
malformed tail	21 (18.10%)	12 (10.43%)	34 (24.29%)	35 (28.00%)	25 (25.25%)	30 (40.54%)	51 (58.62%)

C

	controls	empty nano-liposomes
examined larvae	160	170
not developed	18 (11.25%%)	12 (7.05%)
severely malf. larvae	17 (10,60%)	11 (6.47%)
healthy larvae	125 (78.12%)	147 (86.47%)